Hormonal
GLP-1 receptor agonists (GLP-1RAs) reduce major adverse cardiovascular events (MACE) in type 2 diabetes patients through pleiotropic mechanisms including blood pressure reduction, improved endothelial function, and anti-inflammatory effects, independent of weight loss.
If you have type 2 diabetes and are at risk for heart problems, GLP-1 receptor agonists (like semaglutide or liraglutide) offer heart protection beyond just lowering blood sugar. They work by improving blood vessel function and lowering blood pressure. While they are injections that can cause stomach upset, the cardiovascular benefits are significant and often independent of weight loss.
GLP-1RAs favourably modulate cardiovascular risk parameters, some of which are independent of weight loss, HbA1c reductions or the occurrence of severe hypoglycaemia. GLP-1RAs may mediate effects on cardiovascular outcomes through effects on other risk factors such as blood pressure, dyslipidaemia, platelet reactivity, endothelial dysfunction, and insulin sensitivity, as well as direct cardioprotective effects.
Why this rating
Based on a review of large clinical trials and mechanistic studies, though specific trial data is summarized rather than presented as raw primary data.
Source
GLP-1RAs in type 2 diabetes: mechanisms that underlie cardiovascular effects and overview of cardiovascular outcome data
Andrei C. Spósito et al. · Cardiovascular Diabetology · 2018
DOI 10.1186/s12933-018-0800-2
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →